DoD Gulf War Illness Innovative Treatment Evaluation Award
Opportunity Identification: W81XWH 10 GWIRP ITEA
Opportunity summary
A key feature of this opportunity is its emphasis on "systematic evaluation" of innovative treatments rather than basic discovery work. In other words, the program is looking for preliminary clinical or translational studies designed to generate credible early evidence about whether an intervention is promising. The announcement highlights that these initial results are expected to lay the groundwork for later, larger-scale efficacy trials. That signals a development pipeline: ITEA funding is meant to reduce uncertainty, produce measurable outcomes, and justify a subsequent, more definitive study if the early findings support moving forward.
The award mechanism includes both cooperative agreements and grants, and it is categorized as discretionary funding within Science and Technology and other Research and Development. The total estimated funding for the opportunity was $1,440,000, with an expectation of making about two awards. There is no cost sharing or matching requirement, which typically makes it easier for a wide range of organizations to apply without needing to contribute non-federal funds.
Eligibility is listed as unrestricted, meaning the opportunity was broadly open to many types of applicants (such as universities, nonprofits, companies, and other organizations), subject to any additional eligibility clarifications that may have been included in the full announcement text. The CFDA listing associated with the program is 12.420 (Military Medical Research and Development), which reflects its placement within the DoD medical R&D portfolio.
In terms of timing, the opportunity was posted on April 14, 2010, and had an application deadline of August 4, 2010. The archive date was September 3, 2010, indicating it is no longer active but remains part of the historical record of DoD funding opportunities. For applicant support and technical issues related to accessing the full announcement or submitting materials, the notice provided points of contact through PA HELP and the CDMRP eReceipt/CDMRP Help Desk, including phone numbers and email addresses.
Overall, this grant opportunity was designed to push forward treatment options for Gulf War Illness by funding carefully planned preliminary evaluations of interventions that are genuinely new to this veteran population. The expected output is actionable early evidence that can guide whether and how to invest in larger, more definitive clinical studies aimed at improving real-world functioning and quality of life for ill Gulf War veterans.
Frequently asked questions
What is the DoD Gulf War Illness Innovative Treatment Evaluation Award (ITEA)?
The Innovative Treatment Evaluation Award (ITEA) is a U.S. Department of Defense (DoD) research funding opportunity under the Gulf War Illness Research Program (GWIRP). It was designed to support early-stage, structured testing of new and creative treatment approaches intended to improve health and functional status for Gulf War veterans who are ill.
What is the funding opportunity number for this program?
The funding opportunity number is W81XWH-10-GWIRP-ITEA.
Which agency administers this funding opportunity?
The program is administered through the U.S. Army Medical Research Acquisition Activity (USAMRAA) on behalf of the DoD GWIRP.
What is the main goal of the ITEA program?
The central goal is practical and patient-focused: to identify interventions that can improve health and functional status for affected Gulf War veterans, particularly by exploring treatment ideas that have not already been studied in this specific population.
What kinds of projects was ITEA intended to support?
ITEA emphasized systematic evaluation of innovative treatments rather than basic discovery. It targeted preliminary clinical or translational studies that are structured to generate credible early evidence about whether an intervention appears promising for Gulf War Illness.
Does this opportunity fund basic research or discovery science?
Based on the description provided, the emphasis is not on basic discovery work. The focus is on systematic evaluation and early evidence generation for potential treatments.
What does "systematic evaluation" mean in the context of this award?
In this context, "systematic evaluation" refers to carefully planned preliminary studies (clinical or translational) that measure outcomes and reduce uncertainty about whether an intervention is worth advancing. The intention is to produce credible early results rather than exploratory or purely theoretical findings.
How are the results from ITEA studies expected to be used?
The announcement indicated that early results are expected to lay the groundwork for later, larger-scale efficacy trials. In other words, ITEA funding was positioned as a step in a development pipeline that supports moving promising treatments toward more definitive testing.
What funding mechanisms were included under this opportunity?
The award mechanism included both cooperative agreements and grants.
How much total funding was estimated for this opportunity?
The total estimated funding was $1,440,000.
About how many awards were expected to be made?
The opportunity anticipated making about two awards.
Was cost sharing or matching required?
No. The opportunity specified there was no cost sharing or matching requirement.
Who was eligible to apply?
Eligibility was listed as unrestricted, meaning it was broadly open to many types of applicants (for example, universities, nonprofits, companies, and other organizations), subject to any additional eligibility clarifications that may have been included in the full announcement.
What is the CFDA number associated with this program?
The CFDA listing associated with the program is 12.420 (Military Medical Research and Development).
When was the opportunity posted?
The opportunity was posted on April 14, 2010.
What was the application deadline?
The application deadline was August 4, 2010.
Is this grant opportunity still active?
No. The archive date was September 3, 2010, which indicates the opportunity is no longer active and is part of the historical record of DoD funding opportunities.
What type of funding category did this fall under?
It was categorized as discretionary funding within Science and Technology and other Research and Development.
Where could applicants get help with technical or submission issues?
The notice referenced points of contact for support through PA HELP and the CDMRP eReceipt/CDMRP Help Desk, including phone numbers and email addresses, for assistance accessing the full announcement or submitting materials.
What population was the program focused on?
The program focused on Gulf War veterans who are ill, with the intent to evaluate treatment approaches aimed at improving real-world health, functional status, and quality of life for that population.
What made a treatment approach a good fit for this opportunity?
A strong fit was an intervention that was genuinely new to the Gulf War Illness veteran population and could be evaluated in a structured, early-stage clinical or translational study designed to yield actionable evidence about whether the approach is promising.
Questions about this opportunity?
Contact USGrants.org for help with this listing or similar funding opportunities.
Contact USGrants.orgRelated funding listings
Applicants who have applied for this opportunity (W81XWH 10 GWIRP ITEA) also looked into and applied for these: